BridgeBio Builds Case for Early 2027 Launch of Dystrophy Drug
Data from BridgeBio Pharma’s Phase 3 FORTIFY study show that BBP-418 significantly increases levels of a key disease biomarker that helps stabilize muscles in patients with limb-girdle muscular dystrophy.
BridgeBio Builds Case for Early 2027 Launch of Dystrophy Drug Read More »
